Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2023-10-26 Board/Management Inform…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for November 2, 2023, where the company will consider and approve un-audited financial results for the quarter and half year ended September 30, 2023. It is an intimation to the stock exchanges as per SEBI regulations. The document does not contain any financial data or results itself, nor is it a report or presentation. It is an announcement related to board activities and regulatory compliance. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2023-10-26 English
Board Meeting — MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Company…
Regulatory Filings
2023-10-26 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 ,inter alia, to consider and approve the standalone and consolidated ....
Regulatory Filings Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for November 2, 2023, where the company will consider and approve unaudited financial results for the quarter and half year ended September 30, 2023. It is an intimation to the stock exchanges as per SEBI regulations. The document does not contain actual financial results or detailed reports but is an announcement of a board meeting related to financial results. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release, which require actual financial data or results.
2023-10-26 English
Loss of Share Certificates
Regulatory Filings
2023-10-25 English
Please find attached details of issuance of letter of confirmations w.r.t., issue of duplicate shares.
Regulatory Filings
2023-10-25 English
Intimation of loss of share certificate.
Regulatory Filings
2023-10-21 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.